Novartis AG Total Long Term Liabilities 2010-2024 | NVS

Novartis AG total long term liabilities from 2010 to 2024. Total long term liabilities can be defined as the sum of all non-current liabilities.
  • Novartis AG total long term liabilities for the quarter ending September 30, 2024 were $31.951B, a 22.61% increase year-over-year.
  • Novartis AG total long term liabilities for 2023 were $26.805B, a 8.75% decline from 2022.
  • Novartis AG total long term liabilities for 2022 were $29.374B, a 13% decline from 2021.
  • Novartis AG total long term liabilities for 2021 were $33.765B, a 11.27% decline from 2020.
Novartis AG Annual Total Long Term Liabilities
(Millions of US $)
2023 $26,805
2022 $29,374
2021 $33,765
2020 $38,053
2019 $34,555
2018 $37,264
2017 $35,449
2016 $33,024
2015 $30,726
2014 $27,570
2013 $25,414
2012 $30,877
2011 $28,408
2010 $28,891
2009 $18,573
Novartis AG Quarterly Total Long Term Liabilities
(Millions of US $)
2024-09-30 $31,951
2024-06-30 $27,991
2024-03-31 $25,290
2023-12-31 $26,805
2023-09-30 $26,059
2023-06-30 $27,139
2023-03-31 $29,550
2022-12-31 $29,374
2022-09-30 $29,406
2022-06-30 $32,258
2022-03-31 $33,707
2021-12-31 $33,765
2021-09-30 $34,392
2021-06-30 $40,254
2021-03-31 $41,003
2020-12-31 $38,053
2020-09-30 $43,286
2020-06-30 $40,496
2020-03-31 $40,826
2019-12-31 $34,555
2019-09-30 $35,153
2019-06-30 $34,679
2019-03-31 $34,512
2018-12-31 $37,264
2018-09-30 $36,648
2018-06-30 $37,214
2018-03-31 $36,090
2017-12-31 $35,449
2017-09-30 $37,223
2017-06-30 $37,625
2017-03-31 $38,010
2016-12-31 $33,024
2016-09-30 $34,337
2016-06-30 $32,633
2016-03-31 $32,742
2015-12-31 $30,726
2015-09-30 $27,984
2015-06-30 $27,192
2015-03-31 $29,438
2014-12-31 $27,570
2014-09-30 $27,337
2014-06-30 $27,695
2014-03-31 $30,236
2013-12-31 $25,414
2013-09-30 $26,603
2013-06-30 $27,056
2013-03-31 $27,494
2012-12-31 $30,877
2012-09-30 $32,155
2012-06-30 $29,331
2012-03-31 $28,854
2011-12-31 $28,408
2011-09-30 $29,406
2011-06-30 $29,286
2011-03-31 $29,662
2010-12-31 $28,891
2010-09-30 $30,753
2010-06-30 $23,279
2010-03-31 $23,147
2009-12-31 $18,573
2009-09-30 $19,471
2009-06-30 $18,428
2009-03-31 $16,752
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $217.584B $45.440B
Novartis has one of the strongest and broadest portfolio of oncology drugs and generics. It continues to build depth in 5 core therapeutic areas Cardio-Renal, Immunology, Neuroscience, Oncology and Hematology, strength in technology platforms - Targeted Protein Degradation, Cell Therapy, Gene Therapy, Radioligand Therapy, and xRNA. Novartis efforts to strengthen its wide and deep oncology portfolio by developing breakthrough treatments. Cosentyx, Entresto, Kesimpta, Zolgensma, Kisqali and Leqvio. In March 2015, Novartis acquired certain oncology products and pipeline compounds from Glaxo. In exchange, it sold its non-influenza Vaccines business to Glaxo. Also, the company has spun off the Alcon business into a separate company. In January 2015, Novartis divested its Animal Health division to Lilly. In July 2015, the company divested its influenza vaccines business to CSL Limited. Novartis has also acquired The Medicines Company, adding Leqvio, to its portfolio. Novartis sold its investment in Roche.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $789.394B 81.76
Novo Nordisk (NVO) Denmark $481.063B 34.69
Johnson & Johnson (JNJ) United States $374.313B 15.18
AbbVie (ABBV) United States $352.544B 18.56
Merck (MRK) United States $260.350B 17.30
AstraZeneca (AZN) United Kingdom $199.957B 17.81
Pfizer (PFE) United States $151.422B 10.36
Sanofi (SNY) $130.241B 11.80
Innoviva (INVA) United States $1.263B 10.51